Clinical trials
HER2 Positive clinical trials
Below are recruiting her2 positive clinical trials, each written for real people, not researchers. We’re tracking 344 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06328465Recruiting
MRI for early detection of breast cancer spread
This trial is testing a new way to use MRI scans to find breast cancer that has spread to other parts of the body early. It is for people who have had aggressive breast cancer (HER2 positive or triple negative) and finished treatment with surgery, but still have a higher risk of the cancer coming back.
MilanAges 18–75 - NCT06087120Recruiting
Can a blood test predict breast cancer treatment response?
This study looks at whether a blood test (ctDNA) can help predict how well breast cancer responds to chemotherapy before surgery. It focuses on people with HER2-positive or triple-negative breast cancer that has not spread far.
JakartaAges 18 years+ - NCT06282575RecruitingPhase 3
Zanidatamab plus chemo for advanced HER2-positive bile duct cancer
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
Duarte, CaliforniaAges 18 years+ - NCT06178159RecruitingPhase 2
New drug combo before surgery for HER2-positive breast cancer
This trial tests a new combination of drugs (DV plus pertuzumab, with or without toripalimab) given before surgery for HER2-positive breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06220214RecruitingEarly Phase 1
Study of chemo before breast cancer surgery with special mammogram
This trial tests whether a special mammogram with contrast can help doctors see how well chemotherapy is working before breast cancer surgery. It is for women who plan to have at least 4 rounds of chemo before their operation.
Stony Brook, New YorkAges 18 years+ - NCT05800275RecruitingPhase 2
Tucatinib and capecitabine plus spinal trastuzumab for HER2+ cancer
This Phase 2 trial tests a combination of tucatinib and capecitabine (taken by mouth) plus trastuzumab delivered into the spinal fluid, to treat breast cancer that has spread to the leptomeninges (lining around the brain/spinal cord). It may help reduce cancer activity in the spinal fluid and improve symptoms.
BordeauxAges 18 years+ - NCT05910398RecruitingPhase 3
Extending anti-HER2 treatment after breast cancer surgery
This Phase 3 trial tests whether continuing or pausing the anti-HER2 medicine pyrotinib after surgery can lower the chance that invasive HER2-positive breast cancer comes back. It may help people who have recently finished trastuzumab or T-DM1 and are well enough to take tablets.
ShanghaiAges 18 years+ - NCT05982678RecruitingPhase 2
Study of a drug for breast cancer that has spread to a few spots
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
AmsterdamAges 18 years+ - NCT05969860RecruitingPhase 2
Home cancer treatment vs clinic treatment for advanced cancer
This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.
Jacksonville, FloridaAges 18 years+ - NCT05893966Recruiting
Tested extra radiation to the tumor area in HER2-positive breast cancer
This study follows people with HER2-positive invasive breast cancer to see how adding radiation to the tumor bed may affect outcomes. It may be most relevant if you are scheduled for breast radiation and have not had radiation to the same side before.
Seoul, SeoulAges 19 years+ - NCT05894239RecruitingPhase 3
Tested targeted drug for HER2-positive breast cancer with PIK3CA changes
This Phase 3 study tests inavolisib plus Phesgo versus placebo plus Phesgo in people whose breast cancer has both HER2-positive and PIK3CA-mutated tumor markers. The goal is to see if adding inavolisib improves how well the treatment controls the cancer and how safe it is.
Gilbert, ArizonaAges 18 years+ - NCT05837806RecruitingPhase 2
Tislelizumab and disitamab as pre-surgery treatment for HER2 UTUC
This trial tests whether giving tislelizumab plus disitamab vedotin before surgery (neoadjuvant therapy) can improve outcomes for people with HER2-positive, high-risk upper tract urothelial cancer. It also looks at the treatment’s safety and helps doctors learn if certain tumor features predict response.
TianjinAges 18 years+ - NCT05748834RecruitingPhase 2
Tucatinib plus Doxil for HER2-positive metastatic breast cancer
This Phase 2 study tests tucatinib (a HER2-targeted pill) plus Doxil (a chemotherapy medicine) to slow or shrink HER2-positive metastatic breast cancer that has been treated before. It may help by targeting HER2 cancer cells more effectively than past treatments alone.
Columbia, MarylandAges 18 years+ - NCT05672524RecruitingPhase 2
Tucatinib plus trastuzumab for HER2-positive rectal cancer
This Phase 2 study tests whether tucatinib combined with trastuzumab can slow or shrink rectal cancer that is HER2-positive and has certain genetic tumor features. If you qualify, you may benefit from a targeted treatment approach aimed at the HER2 pathway.
Basking Ridge, New JerseyAges 18 years+ - NCT05673928RecruitingPhase 2
Tucatinib and T-DM1 for HER2-positive brain-metastasis tumors
This Phase 2 study tests tucatinib plus T-DM1 (ado-trastuzumab emtansine) in people with HER2-positive metastatic solid tumors that have spread to the brain. It aims to shrink brain and body tumors and help control cancer that is progressing in the brain.
Houston, TexasAges 18 years+ - NCT05461768RecruitingPhase 1
BL-M07D1 for HER2-positive or HER2-low breast cancer
This Phase 1 study tests BL-M07D1, a new investigational medicine, in people with HER2-positive or HER2-low breast cancer (and other solid tumors) that can’t be operated on or has spread. It aims to find a safe dose and learn how well the treatment may work based on HER2 levels in tumor tissue.
Fuzhou, FujianAges 18–75 - NCT05150691RecruitingPhase 1/Phase 2
Early study of an HER2 drug in advanced solid tumors
This early-phase trial tests DB-1303 and BNT323 together in people with advanced or metastatic solid cancers that have specific HER2 features. It may be an option when standard treatments have stopped working, aiming to find a safer dose and early signs of effectiveness.
Cerritos, CaliforniaAges 18 years+ - NCT05187832RecruitingPhase 1
Study drug for ER-positive, HER2-negative breast cancer in postmenopausal women
This Phase 1 trial tests AND019, a new study drug, in postmenopausal women with advanced or metastatic ER-positive and HER2-negative breast cancer. It aims to see if the drug is safe and can control the cancer when other standard treatments have stopped working.
Nashville, TennesseeAges 18 years+ - NCT04968964Recruiting
Monitoring test for CDK4/6 drugs in metastatic breast cancer
This study follows people with hormone receptor–positive, HER2-negative metastatic breast cancer who are taking CDK4/6 inhibitor treatment (with or without an added blood test called DiviTum®). The goal is to see how well the standard treatment is working and whether DiviTum® (a serum TK1 activity test) can help guide monitoring.
St Louis, MissouriAges 18 years+ - NCT04899908RecruitingPhase 2
Brain radiation with or without gadolinium nanoparticles for brain metastases
This trial tests whether adding tiny gadolinium-containing nanoparticles to standard brain radiation can better control brain metastases from certain cancers. It is for people with tumors that have grown after immunotherapy, are from certain cancers (like melanoma, GI, or HER2+ breast), are cystic, are large, or have come back after prior radiation.
Boston, MassachusettsAges 18 years+ - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
San Francisco, CaliforniaAges 18 years+ - NCT04150640RecruitingPhase 2
Chemo drug combination for advanced stomach or esophagus cancer
This Phase 2 trial tests whether a combination of chemo drugs (oxaliplatin and liposomal irinotecan) plus trastuzumab works better for people with advanced stomach or esophagus adenocarcinoma that has specific tumor markers (HER2 and PDL1). It may help shrink tumors and improve control of the cancer in people who have not had prior treatment for advanced disease.
Madison, WisconsinAges 18 years+ - NCT03383978RecruitingPhase 1
Test brain injections plus IV antibody for HER2-positive glioblastoma
This early-phase study tests a combination of cells injected directly into the brain and an IV antibody to treat recurrent HER2-positive glioblastoma (or a related tumor, gliosarcoma). It may help by attacking the tumor locally in the brain while the antibody boosts the immune system’s response.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT02945579Recruiting
Testing skipping breast surgery or radiation for top responders
This trial studies whether some people with early-stage breast cancer who respond extremely well to hormone/chemo/targeted treatment can safely skip breast surgery and/or radiation. It aims to reduce side effects without increasing cancer risk in carefully selected patients.
Gilbert, ArizonaAges 30 years+
Hear when a new HER2 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 positive?
- Yes. Clin2 currently lists 344 recruiting her2 positive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 positive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 positive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.